Bioxyne Company Profile
Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues.
Location
Suite 1005
4 Bridge Street
Sydney
NSW 2000
NSW 2000
AUSTRALIA
Contact
Phone: +61 (0) 407-218-922
News Articles
Bioxyne fails in PhIIb with COPD drug, hopes for subset rescue from under-65s
Australian immunotherapeutics business Bioxyne is pinning its hopes the on the continued development of its immunotherapeutic, HI 164 OV for chronic obstructive pulmonary disease (COPD) in a specific...
Bioxyne reports Phase IIb COPD data for HI-164OV
Bioxyne Ltd. (ASX:BXN) reported preliminary data from the Phase IIb HI-H005 trial to treat moderate to severe chronic obstructive pulmonary disease (COPD) showing that oral HI-164OV did not reduce the...
Bioxyne reports the results from the Phase IIb COPD study
Bioxyne Limited has received the preliminary analysis of the study 005 which examines the efficacy and safety of the immunotherapeutic, HI 164 OV in patients with chronic obstructive pulmonary disea...
Bioxyne reports the results from the Phase IIb study
Analysis of the full patient population indicates that there was no significant benefit of the immunotherapeutic across the study group as a whole. Subset analysis in patients under 65 yea...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company&rs...
More Information about "Bioxyne" on BioPortfolio
We have published hundreds of Bioxyne news stories on BioPortfolio along with dozens of Bioxyne Clinical Trials and PubMed Articles about Bioxyne for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bioxyne Companies in our database. You can also find out about relevant Bioxyne Drugs and Medications on this site too.
